Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2012-08-24

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm300580yPMID 22876932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.

  2012cited by this paper
• Pt(IV) complexes as prodrugs for cisplatin.

  2012cited by this paper
• Platinum(IV) prodrugs entrapped within multiwalled carbon nanotubes: Selective release by chemical reduction and hydrophobicity reversal

  2012cited by this paper
• Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity.

  2011cited by this paper
• Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

  2011cited by this paper
• Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.

  2011cited by this paper
• Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin

  2011cited by this paper
• Anticancer platinum (IV) prodrugs with novel modes of activity.

  2011cited by this paper
• Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione.

  2010cited by this paper
• Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.

  2010cited by this paper
• New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.

  2010cited by this paper
• Inhibition of transcription by platinum antitumor compounds.

  2009cited by this paper
• Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue

  2008cited by this paper
• Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake.

  2007cited by this paper
• Basis for design and development of platinum(IV) anticancer complexes.

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• 195Pt NMR--theory and application.

  2007cited by this paper
• Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells.

  2007cited by this paper
• A potent cytotoxic photoactivated platinum complex

  2007cited by this paper
• Testicular germ-cell cancer.

  2006cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• The antioxidant function of the p53 tumor suppressor

  2005cited by this paper
• Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

  2005cited by this paper
• Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake.

  2005cited by this paper
• Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.

  2005cited by this paper
• Analysis of Platinum Adducts with DNA Nucleotides and Nucleosides by Capillary Electrophoresis Coupled to ESI‐MS: Indications of Guanosine 5′‐Monophosphate O6–N7 Chelation

  2004cited by this paper
• Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes.

  2004cited by this paper
• The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines.

  2004cited by this paper
• Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance.

  2003cited by this paper
• A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

  2002cited by this paper
• Electrochemistry, Protein Binding and Crystal Structures of Platinum(II) and Platinum(IV) Carboxylato Complexes

  2002cited by this paper
• Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

  2002cited by this paper
• Calculation of the hydrophobicity of platinum drugs.

  2001cited by this paper
• Synthesis of New Taxol Side Chain Precursor from L-Tartaric Ester.

  2001cited by this paper
• Reduction of the anti-cancer drug analogue cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by L-cysteine and L-methionine and its crystal structure†

  1999cited by this paper
• Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells.

  1999cited by this paper
• A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV)

  1999cited by this paper
• Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

  1999cited by this paper
• Reduction and Anticancer Activity of Platinum(IV) Complexes

  1998cited by this paper
• Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.

  1998cited by this paper
• Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes.

  1997cited by this paper
• Carboxylation of Dihydroxoplatinum(IV) Complexes via a New Synthetic Pathway.

  1996cited by this paper
• DNA interactions of antitumor platinum(IV) complexes.

  1995cited by this paper
• The Influence of the Axial Ligands of a Series of Platinum(IV) Anti-Cancer Complexes on Their Reduction to Platinum(II) and Reaction With DNA

  1995cited by this paper
• Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

  1995cited by this paper
• CALCULATING LOG POCT FROM STRUCTURES

  1993cited by this paper
• Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.

  1992cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.

  1987cited by this paper
• Reaction products from platinum(IV) amine compounds and 5'-GMP are mainly bis(5'-GMP)platinum(II) amine adducts.

  1986cited by this paper
• A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate.

  1984cited by this paper
• Platinum-195 nuclear magnetic resonance

  1982cited by this paper
• p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure

  1964cited by this paper

• Preparation of trans,trans-[Pt(py)2(N3)2(OH)2] via Photoinduced Reactivity of [Pt(NO3)6]2- Anion.

  2025cites this paper
• Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs

  2025cites this paper
• New Multifunctional Platinum (IV) Complexes Incorporating Cannabidiol Active Moieties Elicit Mitochondrial Damage and Synergistically Boost Antitumor Efficacy

  2025cites this paper
• Application of Hypoxia-Activated Prodrugs in Tumor Therapy: Design Strategies and Perspectives.

  2025cites this paper
• The novel platinum(IV) prodrug of cisplatin axially conjugated with cannabidiol induces mitochondrial dysfunction and synergistically enhances anti-tumor effects.

  2025cites this paper
• Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment.

  2024cites this paper
• Recent updates in nanoscale delivery systems of platinum(IV) antitumor prodrugs

  2024cites this paper
• Thermoresponsive carboplatin-releasing prodrugs.

  2024cites this paper
• Exploring the Impact of Head Group Modifications on the Anticancer Activities of Fatty-Acid-like Platinum(IV) Prodrugs: A Structure–Activity Relationship Study

  2023cites this paper
• Strategy to Regulate the Stability and Reduction Rate of Oxaliplatin-Based Pt(IV) Complexes: Cocrystallization

  2023cites this paper
• Platinum(IV) combo prodrugs containing cyclohexane-1R,2R-diamine, valproic acid, and perillic acid as a multiaction chemotherapeutic platform for colon cancer.

  2023cites this paper
• Platinum(II) 5-substituted-8-hydroxyquinoline coordination compounds induces mitophagy-mediated apoptosis in A549/DDP cancer cells.

  2023cites this paper
• Heavy-Metal Trojan Horse: Enterobactin-Directed Delivery of Platinum(IV) Prodrugs to Escherichia coli.

  2022cites this paper
• Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration

  2022cites this paper
• Preparation of cisplatin delivery calcium phosphate nanoparticles using poly(Pt(IV) prodrug) as the payload

  2022cites this paper
• Platinum(iv)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light†

  2021cites this paper
• Ultrasound‐Triggered Delivery of Iproplatin from Microbubble‐Conjugated Liposomes

  2021cites this paper
• Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs

  2021cites this paper
• Facile Synthesis of a Pt(IV) Prodrug of Cisplatin and Its Intrinsically 195mPt Labeled Analog: A Step Closer to Cancer Theranostic

  2021cites this paper
• A Review on Carbon Nanotubes on Cancer Therapy

  2021cites this paper
• Synthesis of 2-deoxy-d-glucose coated Fe3O4 nanoparticles for application in targeted delivery of the Pt(iv) prodrug of cisplatin – a novel approach in chemotherapy

  2020cites this paper
• Development of a Pre-assembled TBET Fluorescent Probe for Ratiometric Sensing of Anticancer Platinum(ll) Complexes.

  2020cites this paper
• Anhydride Post-Synthetic Modification in a Hierarchical Metal-Organic Framework.

  2020cites this paper
• Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.

  2020cites this paper
• Tansition Metal-Based Prodrugs for Anticancer Drug Delivery.

  2020cites this paper
• On the stability and biological behavior of Pt(IV) complexes with halido and aryl ligands in the axial positions

  2020cites this paper
• Supercritical CO2 Processing Generates Aqueous Cisplatin Solutions with Enhanced Cancer Specificity

  2020cites this paper
• The influence of the nonleaving group on the anticancer activity of tetrachlorido platinum(IV) complexes with pyridine/bipyridine derivatives

  2019cites this paper
• Design, synthesis and biological evaluation of a novel platinum(II) complex possessing bioreductive groups for cancer therapy

  2019cites this paper
• Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.

  2019cites this paper
• Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies

  2019cites this paper
• Antitumor Activity of Cyclodextrin-based Supramolecular Platinum Prodrug In vitro and In vivo

  2019cites this paper
• Ruthenium arene complex induces cell cycle arrest and apoptosis through activation of P53-mediated signaling pathways

  2019cites this paper
• A view on multi-action Pt(IV) antitumor prodrugs

  2019cites this paper
• Two novel platinum(II) complexes with sorafenib and regorafenib: Synthesis, structural characterization, and evaluation of in vitro antitumor activity

  2019cites this paper
• Anti-tumor platinum (IV) complexes bearing the anti-inflammatory drug naproxen in the axial position

  2019cites this paper
• Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.

  2018cites this paper
• Dual-targeting antitumor hybrids derived from Pt(IV) species and millepachine analogues.

  2018cites this paper
• Synergic highly effective photothermal-chemotherapy with platinum prodrug linked melanin-like nanoparticles

  2018cites this paper
• Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance

  2018cites this paper
• Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.

  2018cites this paper
• Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(iv) pro-drug based on Cisplatin and Tranilast.

  2018cites this paper
• Stimuli-Responsive Therapeutic Metallodrugs.

  2018cites this paper
• A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes.

  2018cites this paper
• Probing the Platinum(IV) Prodrug Hypothesis. Are Platinum(IV) Complexes Really Prodrugs of Cisplatin

  2018cites this paper
• Synthesis, characterization, DNA binding, cytotoxicity and molecular docking properties of Cu (II) and Mn (II) complexes with 1,4-bis (pyrazol-1-yl) terephthalic acid

  2018cites this paper
• Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches

  2018cites this paper
• Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.

  2017cites this paper
• Oxidative Stress Induced by Pt ( IV ) Prodrugs Based on the Cisplatin

  2017cites this paper
• Anticancer Platinum(IV) Prodrugs Containing Monoaminophosphonate Ester as a Targeting Group Inhibit Matrix Metalloproteinases and Reverse Multidrug Resistance.

  2017cites this paper
• Synthesis, characterization and in vitro and in vivo anticancer activity of Pt(iv) derivatives of [Pt(1S,2S-DACH)(5,6-dimethyl-1,10-phenanthroline)].

  2017cites this paper
• Organoruthenium(II) compounds with pyridyl benzoxazole/benzthiazole moiety: studies on DNA/protein binding and enzyme mimetic activities

  2017cites this paper
• Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.

  2017cites this paper
• Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(iv) prodrug for liver cancer therapy.

  2017cites this paper
• Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure–Activity Relationship and Application as Orally Available Prodrugs

  2017cites this paper
• Exploring the Hydrolytic Behavior of the Platinum(IV) Complexes with Axial Acetato Ligands.

  2017cites this paper
• Production of nanostructured molecular liquids by supercritical CO2 processing

  2017cites this paper
• Prodrug approach: An overview of recent cases.

  2017cites this paper
• Prediction of logP for Pt(II) and Pt(IV) complexes: Comparison of statistical and quantum-chemistry based approaches.

  2016cites this paper
• Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d

  2016cites this paper
• Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs.

  2016cites this paper
• Platinum(IV) prodrug conjugated Pd@Au nanoplates for chemotherapy and photothermal therapy.

  2016cites this paper
• Cytotoxicity-boosting of kiteplatin by Pt(IV) prodrugs with axial benzoate ligands.

  2016cites this paper
• Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position

  2016cites this paper
• Internalization of Ineffective Platinum Complex in Nanocapsules Renders It Cytotoxic.

  2016cites this paper
• Comprehensive Vibrational Spectroscopic Investigation of trans,trans,trans-[Pt(N3)2(OH)2(py)2], a Pt(IV) Diazido Anticancer Prodrug Candidate

  2016cites this paper
• Carbon nanotubes as cancer therapeutic carriers and mediators

  2016cites this paper
• Synthesis, Crystal Structure, and Cytotoxiciy In Vitro of a Zinc(II) Complex

  2015cites this paper
• Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines.

  2015cites this paper
• Host–guest inclusion systems of Pt(IV)-bis(benzoato) anticancer drug candidates and cyclodextrins

  2015cites this paper
• Platinum(IV) Carboxylate Prodrug Complexes as Versatile Platforms for Targeted Chemotherapy.

  2015cites this paper
• Metal complex interactions with DNA.

  2015cites this paper
• Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance

  2015cites this paper
• Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.

  2015cites this paper
• Dense diamond nanoneedle arrays for enhanced intracellular delivery of drug molecules to cell lines

  2015cites this paper
• Novel antitumor cisplatin and transplatin derivatives containing 1-methyl-7-azaindole: synthesis, characterization, and cellular responses.

  2015cites this paper
• Induction of immunogenic cell death by chemotherapeutic platinum complexes.

  2015cites this paper
• Remarkable anticancer activity of ferrocenyl-terpyridine platinum(ii) complexes in visible light with low dark toxicity.

  2014cites this paper
• Synthesis and in vitro characterization of platinum(II) anticancer coordinates using FTIR spectroscopy and NCI COMPARE: A fast method for new compound discovery.

  2014cites this paper
• Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance

  2014cites this paper
• Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(IV) prodrugs

  2014cites this paper
• Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications

  2014cites this paper
• Dissymmetric thiosemicarbazone ligands containing substituted aldehyde arm and their ruthenium(II) carbonyl complexes with PPh3/AsPh3 as ancillary ligands: Synthesis, structural characterization, DNA/BSA interaction and in vitro anticancer activity

  2014cites this paper
• Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.

  2014cites this paper
• Exploring the Scope of [Pt2(4-FC6H4)4(μ-SEt2)2] as a Precursor for New Organometallic Platinum(II) and Platinum(IV) Antitumor Agents

  2014cites this paper
• A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.

  2014cites this paper
• A new entry to asymmetric platinum(IV) complexes via oxidative chlorination.

  2014cites this paper
• Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.

  2014cites this paper
• Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment.

  2014cites this paper
• trans,cis,cis‐Bis(benzoato)dichlorido(cyclohexane‐1R,2R‐diamine)platinum(IV): a Prodrug Candidate for the Treatment of Oxaliplatin‐Refractory Colorectal Cancer

  2014cites this paper
• Effect of zinc oxide nanomaterials-induced oxidative stress on the p53 pathway.

  2013cites this paper
• Synthetic methods for the preparation of platinum anticancer complexes.

  2013cites this paper
• A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold.

  2013cites this paper
• Carbon nanotubes for delivery of small molecule drugs.

  2013cites this paper
• Anti-cancer medicinal aspirin platinum complex and preparation method thereof

  2012cites this paper